Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | PPARA | Q07869 | 4/20 | 0.60 |
| ▸ | PPARG | P37231 | 3/20 | 0.60 |
| ▸ | LTA4H | P09960 | 2/20 | 0.60 |
| ▸ | PPARD | Q03181 | 1/20 | 0.60 |
| ▸ | LAP3 | P28838 | 1/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.57 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 3/20 | 0.54 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4756342 | 1.00 | L3MBTL1 (0.65) | L3MBTL1LMNAPPARAPPARGLTA4H | |
| SCHEMBL5375675 | 1.00 | L3MBTL1 (0.65) | L3MBTL1LMNAPPARAPPARGLTA4H | |
| SCHEMBL27854776 | 0.90 | LTA4H (0.71) | LMNAPPARAPPARGLTA4HPPARD | |
| SCHEMBL6738407 | 0.89 | LTA4H (0.57) | L3MBTL1LMNAPPARAPPARGLTA4H | |
| SCHEMBL6738411 | 0.89 | LTA4H (0.57) | L3MBTL1LMNAPPARAPPARGLTA4H | |
| SCHEMBL4755605 | 0.89 | L3MBTL1 (0.52) | L3MBTL1LMNAPPARAPPARGLTA4H | |
| SCHEMBL2164928 | 0.87 | LTA4H (0.72) | PPARAPPARGLTA4HPPARDLAP3 | |
| SCHEMBL6732617 | 0.87 | LTA4H (0.72) | PPARAPPARGLTA4HPPARDLAP3 | |
| SCHEMBL9493387 | 0.87 | L3MBTL1 (0.67) | L3MBTL1LMNAPPARAPPARGLTA4H | |
| SCHEMBL5309375 | 0.87 | LTA4H (0.72) | PPARAPPARGLTA4HPPARDLAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3024816-B1 | PPAR-SPARING COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | METABOLIC SOLUTIONS DEV CO LLC (US) | 2020-06-03 | — | — | EP | disclosed |
| US-9562012-B2 | PPAR-sparing compounds for the treatment of metabolic diseases | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562012-B2 | PPAR-sparing compounds for the treatment of metabolic diseases | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160152570-A1 | PPAR-SPARING COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | ALZHEIMER'S DRUG DISCOVERY FOUNDATION | 2016-06-02 | — | — | US | disclosed |
| US-20160152570-A1 | PPAR-SPARING COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | ALZHEIMER'S DRUG DISCOVERY FOUNDATION | 2016-06-02 | — | — | US | disclosed |
| WO-2015013187-A1 | PPAR-SPARING COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT CO., LLC (US) | 2015-01-29 | — | — | WO | disclosed |
| US-7919515-B2 | 3-phenylpropionic acid derivatives | ADAMED SP. Z O.O. (PL) | 2011-04-05 | — | — | US | disclosed |
| US-7919515-B2 | 3-phenylpropionic acid derivatives | ADAMED SP. Z O.O. (PL) | 2011-04-05 | — | — | US | disclosed |
| US-7919515-B2 | 3-phenylpropionic acid derivatives | ADAMED SP. Z O.O. (PL) | 2011-04-05 | — | — | US | disclosed |
| US-7629370-B2 | 3-phenylpropionic acid derivatives | ADAMED SP. Z O.O. (PL) | 2009-12-08 | — | — | US | disclosed |
| CN-1280561-A | Amidocarboxylic acid derivatives | SANKYO CO (JP) | 2001-01-17 | — | — | CN | disclosed |
| EP-1049684-A1 | NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-11-08 | — | — | EP | disclosed |
| WO-2000050414-A1 | NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | DR.REDDY'S RESEARCH FOUNDATION (IN) | 2000-08-31 | — | — | WO | disclosed |
| EP-1026149-A1 | AMIDOCARBOXYLIC ACID DERIVATIVES | Sankyo Company Limited (JP) | 2000-08-09 | — | — | EP | disclosed |
| WO-2000026200-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF NEW ANTIDIABETIC AGENTS | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-05-11 | — | — | WO | disclosed |
| US-6054453-A | HYPOLIPIDEMIC, ANTIHYPERGLYCEMIC USES. | REDD'S RESEARCH FOUNDATION (IN) | 2000-04-25 | — | — | US | disclosed |
| WO-1999019313-A1 | NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-04-22 | — | — | WO | disclosed |
| US-5391565-A | Hypoglycemic agents; antilipemic agents; hypotensive agents | BEECHAN GROUP P.L.C. (GB) | 1995-02-21 | — | — | US | disclosed |
| EP-0542816-A1 | OXAZOLIDINE DIONE DERIVATIVES | BEECHAM GROUP plc (GB) | 1993-05-26 | — | — | EP | disclosed |
| WO-1992002520-A1 | OXAZOLIDINE DIONE DERIVATIVES | BEECHAM GROUP P.L.C. (GB) | 1992-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152570-A1 | PPAR-SPARING COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | PPARG, PPARA, PPARD | L3MBTL1 3403/4885LMNA 2763/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.